Education
About Us
Working with TipRanks
Follow Us
CellSource Co., Ltd. (JP:4880)
:4880
4880 Stock Chart & Stats
¥399.00
¥37.00(4.48%)
At close: 4:00 PM EST
¥399.00
¥37.00(4.48%)
Day’s Range― - ―
52-Week Range¥386.00 - ¥853.00
Previous CloseN/A
Volume210.70K
Average Volume (3M)77.65K
Market Cap
¥7.83B
Enterprise Value¥3.18B
Total Cash (Recent Filing)¥4.63B
Total Debt (Recent Filing)¥241.08M
Price to Earnings (P/E)734.2
Beta0.74
Next Earnings
Mar 17, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield1.24%
Share Statistics
EPS (TTM)-3.81
Shares Outstanding19,827,162
10 Day Avg. Volume73,510
30 Day Avg. Volume77,646
Financial Highlights & Ratios
PEG Ratio-9.83
Price to Book (P/B)1.66
Price to Sales (P/S)2.70
P/FCF Ratio34.51
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue GrowthSustained revenue expansion of +26.49% indicates durable commercial traction for CellSource's cellular therapies. Persistent top-line growth supports continued R&D and scaling of manufacturing, improving the odds of reaching profitable volumes and broader market adoption over months.
Conservative Balance SheetExtremely low leverage gives CellSource long-term financial flexibility critical for biotech development cycles. Minimal debt reduces bankruptcy risk, helps absorb trial setbacks, and enables management to prioritize R&D and strategic partnerships without near-term refinancing pressure.
Diversified Revenue Model & PartnershipsA multi-channel monetization strategy—direct sales, co-development, licensing and grant funding—creates structural resilience. Multiple commercialization pathways lower single-market dependency, share development costs with pharma partners, and increase chances of scalable revenue streams.
Bears Say
Collapsed Net MarginA plunge from 20.47% to 0.29% margin is a material deterioration in profitability that undermines internal funding for trials and commercialization. If margins remain compressed, the company may need external capital, slowing product rollouts and diluting long-term shareholder value.
Declining Return On EquityROE collapsing to 0.18% signals failing efficiency in converting shareholder equity into profits. Persistently low ROE reduces the appeal to long-term investors and suggests capital is not being deployed effectively into high-return programs, constraining organic growth.
Weak Free Cash Flow ConversionNegative and declining free cash flow conversion limits the company's ability to self-fund trials, scale manufacturing, and commercial launches. Persistent FCF weakness forces reliance on dilutive financing or partnerships, which can delay programs and erode long-term shareholder value.
CellSource Co., Ltd. News
4880 FAQ
What was CellSource Co., Ltd.’s price range in the past 12 months?
CellSource Co., Ltd. lowest stock price was ¥386.00 and its highest was ¥853.00 in the past 12 months.
What is CellSource Co., Ltd.’s market cap?
CellSource Co., Ltd.’s market cap is ¥7.83B.
When is CellSource Co., Ltd.’s upcoming earnings report date?
CellSource Co., Ltd.’s upcoming earnings report date is Mar 17, 2026 which is in 28 days.
How were CellSource Co., Ltd.’s earnings last quarter?
CellSource Co., Ltd. released its earnings results on Dec 11, 2025. The company reported -¥3.81 earnings per share for the quarter, missing the consensus estimate of N/A by -¥3.81.
Is CellSource Co., Ltd. overvalued?
According to Wall Street analysts CellSource Co., Ltd.’s price is currently Overvalued.
Does CellSource Co., Ltd. pay dividends?
CellSource Co., Ltd. pays a Annually dividend of ¥5 which represents an annual dividend yield of 1.24%. See more information on CellSource Co., Ltd. dividends here
What is CellSource Co., Ltd.’s EPS estimate?
CellSource Co., Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does CellSource Co., Ltd. have?
CellSource Co., Ltd. has 19,827,162 shares outstanding.
What happened to CellSource Co., Ltd.’s price movement after its last earnings report?
CellSource Co., Ltd. reported an EPS of -¥3.81 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of CellSource Co., Ltd.?
Currently, no hedge funds are holding shares in JP:4880
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
CellSource Co., Ltd.
CellSource Co., Ltd. (4880) is a biotechnology company focused on the development and commercialization of innovative cellular therapies. The company operates primarily in the healthcare sector, specializing in stem cell research and regenerative medicine. CellSource's core products include advanced cellular treatments for various diseases and conditions, leveraging proprietary technology to enhance the efficacy and safety of therapies. The firm aims to transform patient care through its cutting-edge solutions that address unmet medical needs.
Technical Analysis
StemRIM Inc.
―
STELLA PHARMA CORPORATION
―
ReproCELL Inc.
―
StemCell Institute
―
CellSeed Inc.
―